 "EU regulator backs use of GSK-Vir antibody for Covid-19 treatment")
The European Union's drug regulator said on Friday a Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology can be used to treat patients who are at risk of severe disease and do not need supplemental oxygen.
The opinion relates to the use of the treatment, sotrovimab, in adults and adolescents aged 12 years or older and weighing at least 40 kilograms.
"Based on our most recent in vitro data, sotrovimab continues to combat Covid-19 as it evolves and has retained activity against all circulating variants of concern," Vir Chief Executive George Scangos said in a joint statement with GSK.
Interim data from a study of the experimental therapy showed 85% reduction in hospitalization and deaths among Covid-19 patients, GSK and Vir had said.
The rolling review of the drug is ongoing, the European Medicines Agency (EMA) said.
Similar therapies from Eli Lilly and Regeneron Pharmaceuticals have received recommendations from U.S.
and European health regulators earlier this year.
Antibody treatments are designed to decrease the severity of Covid-19 among patients diagnosed with the infection.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%